Acute corneal toxicity of latanoprost with different preservatives

References

• Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 2005;112:1661–1669
   PubMed Web of Science ®Google Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008;53:69–84
   PubMed Web of Science ®Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205–215
   PubMed Web of Science ®Google Scholar
• Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082–1088
   PubMed Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716–726
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl 2008;242:14–19
   PubMedGoogle Scholar
• Chetoni P, Burgalassi S, Monti D, Saettone MF. Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas. Toxicol In Vitro 2003;17:497–504
   PubMed Web of Science ®Google Scholar
• Uematsu M, Kumagami T, Kusano M, et al. Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method. Ophthalmic Res 2007;39:308–314
   PubMed Web of Science ®Google Scholar
• Kusano M, Uematsu M, Kumagami T, et al. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 2010;29:80–85
   PubMed Web of Science ®Google Scholar
• Onizuka N, Uematsu M, Kusano M, et al. Influence of different additives and their concentrations on corneal toxicity and antimicrobial effect of benzalkonium chloride. Cornea 2014;33:521–526
   PubMed Web of Science ®Google Scholar
• Kashiwagi K. Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community. Open Ophthalmol J 2010;28:7–11
   Google Scholar
• Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogs: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123–4128
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312–334
   PubMed Web of Science ®Google Scholar
• Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377–390
   Web of Science ®Google Scholar
• Kruszewski FH, Walker TL, DiPasquale LC. Evaluation of a human corneal epithelial cell line as an in vitro model for assessing ocular irritation. Fundam Appl Toxicol 1997;36:130–140
   PubMedGoogle Scholar
• Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm 2000;207:89–98
   PubMed Web of Science ®Google Scholar
• Monti D, Chetoni P, Burgalassi S, et al. Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation. Int J Pharm 2002;232:139–147
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 1999;16:85–146
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486–490
   PubMed Web of Science ®Google Scholar
• Nakashima M, Nakamura T, Teshima M, et al. Breakdown evaluation of corneal epithelial barrier caused by antiallergic eyedrops using an electrophysiologic method. J Ocul Pharmacol Ther 2008;24:43–51
   PubMed Web of Science ®Google Scholar
• Kaercher T, Hönig D, Barth W. How the most common preservative affects the Meibomian lipid layer. Orbit 1999;18:89–97
   PubMedGoogle Scholar
• Chung SH, Lee SK, Cristol SM, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis 2006;12:415–421
   PubMed Web of Science ®Google Scholar
• Mishra BK, Kuanar M, Chauhan G, Patel N. Behaviour of non-ionic microemulsion containing Tween-80, iso-amyl alcohol, hexane and water. Indian J Chem Technol 2000;7:338–341
   Web of Science ®Google Scholar
• Pauly A, Meloni M, Brignole-Baudouin F, et al. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009;50:1644–1652
   PubMed Web of Science ®Google Scholar
• Liang H, Pauly A, Riancho L, et al. Toxicological evaluation of preservative-containing and preservative free topical prostaglandin analogs on a three dimensional reconstituted corneal epithelium system. Br J Ophthalmol 2011;95:869–875
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Usui T, Yokoo S, et al. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci 2012;53:5154–5160
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Daull P, et al. In vitro and in vivo evaluation of a preservative free cationic emulsion of latanoprost in corneal wound healing models. Cornea 2012;31:1319–1329
   PubMed Web of Science ®Google Scholar
• Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int J Toxicol 2001;20:23–50
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418–423
   PubMed Web of Science ®Google Scholar
• Kim MS, Choi CY, Kim JM, et al. Microbial contamination of multiply used preservative free artificial tears packed in reclosable containers. Br J Ophthalmol 2008;92:1518–1521
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative free glaucoma medications. Eur J Ophthalmol 2007;17:341–349
   PubMed Web of Science ®Google Scholar